Plasma Pro-B-Type Natriuretic Peptide Testing as a Screening Method for Hypertrophic Cardiomyopathy
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
Citação
JOURNAL OF CARDIAC FAILURE, v.18, n.7, p.564-568, 2012
Resumo
Background: Clinical multistage risk assessment associated with electrocardiogram (ECG) and NT-proBNP may be a feasible strategy to screen hypertrophic cardiomyopathy (HCM). We investigated the effectiveness of a screening based on ECG and NT-proBNP in first-degree relatives of patients with HCM. Methods and Results: A total of 106 first-degree relatives were included. All individuals were evaluated by echocardiography, ECG, NT-proBNP, and molecular screening (available for 65 individuals). From the 106 individuals, 36 (34%) had diagnosis confirmed by echocardiography. Using echocardiography as the gold standard, ECG criteria had a sensitivity of 0.71, 0.42, and 0.52 for the Romhilt-Estes, Sokolow-Lyon, and Cornell criteria, respectively. Mean values of NT-ProBNP were higher in affected as compared with nonaffected relatives (26.1 vs. 1290.5, P < .001). The AUC of NT-proBNP was 0.98. Using a cutoff value of 70 pg/mL, we observed a sensitivity of 0.92 and specificity of 0.96. Using molecular genetics as the gold standard, ECG criteria had a sensitivity of 0.67, 0.37, and 0.42 for the Romhilt-Estes, Sokolow-Lyon, and Cornell criteria, respectively. Using a cutoff value of 70 pg/mL, we observed a sensitivity of 0.83 and specificity of 0.98. Conclusion: Values of NT-proBNP above 70 pg/mL can be used to effectively select high-risk first-degree relatives for HCM screening. (J Cardiac Fail 2012;18:564-568)
Palavras-chave
Hypertrophic cardiomyopathy, NT-proBNP, familial screening
Referências
- Ala-Kopsala M, 2010, CLIN CHEM, V56, P1822, DOI 10.1373/clinchem.2010.148775
- Arteaga E, 2005, AM HEART J, V149, P1099, DOI 10.1016/j.ahj.2004.09.049
- Arteaga E, 2005, AM HEART J, V150, P1228, DOI 10.1016/j.ahj.2005.02.045
- Downie PF, 1999, CLIN SCI, V97, P255, DOI 10.1042/CS19990084
- Fox PR, 2011, J VET INTERN MED, V25, P1010, DOI 10.1111/j.1939-1676.2011.00776.x
- Hildebrandt P, 2010, EUR HEART J, V31, P1881, DOI 10.1093/eurheartj/ehq163
- Ho CY, 2010, CIRCULATION, V122, P2430, DOI 10.1161/CIRCULATIONAHA.110.978924
- Ho CY, 2006, CIRCULATION, V113, pE396, DOI 10.1161/CIRCULATIONAHA.105.579268
- Ho CY, 2009, CIRC-CARDIOVASC GENE, V2, P314, DOI 10.1161/CIRCGENETICS.109.862128
- Ho CY, 2002, CIRCULATION, V105, P2992, DOI 10.1161/01.CIR.0000019070.70491.6D
- Ho CY, 2010, CIRCULATION, V122, P2440
- Kaski JP, 2008, HEART, V94, P1307, DOI 10.1136/hrt.2007.126748
- Konno T, 2010, CURR OPIN CARDIOL, V20, P205
- Pagourelias ED, 2010, INT J CLIN PRACT, V64, P511, DOI 10.1111/j.1742-1241.2009.02184.x
- Pieroni M, 2007, J CARD FAIL, V13, P380, DOI 10.1016/j.cardfail.2007.01.011
- Rakowski H, 1996, J Am Soc Echocardiogr, V9, P736, DOI 10.1016/S0894-7317(96)90076-0
- Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4
- Rodrigues SL, 2008, ARQ BRAS CARDIOL, V90, P46, DOI 10.1590/S0066-782X2008000100008
- ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5
- SAVAGE DD, 1978, CIRCULATION, V58, P402
- SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1
- Tschope C, 2005, EUR HEART J, V26, P2277, DOI 10.1093/eurheartj/ehi406
- Yamada H, 2002, J AM SOC ECHOCARDIOG, V15, P1238, DOI 10.1067/mje.2002.12877